Keltjens to step in at JenaValve as Drachman departs
This article was originally published in Clinica
David Drachman has resigned as CEO of German transcatheter aortic valve developer JenaValve after six months, and will be replaced by industry veteran and board chair Jan Keltjens on an interim basis. The company did not say exactly why Mr Drachman decided to leave the company, but that it was due to “non-business-related personal reasons.” He joined the firm in July 2014. Mr Keltjens will take up the reins immediately, until a permanent replacement for Mr Drachman is found. Mr Keltjens joined JenaValve’s board in April and became chair in October. He was most recently CEO of Sapiens Steering Brain Simulation, which was acquired by Medtronic last year. JenaValve already markets its CE-marked transapical TAVI device in Europe and “other markets worldwide”; it plans to CE mark and launch its transfemoral device in Europe in 2016.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.